SCHEDULE: Biotechnology Value Fund Group Discloses Passive Stake in CytomX Therapeutics

A group of investment entities led by Biotechnology Value Fund (BVF) has disclosed a passive beneficial ownership of 3.5% of CytomX Therapeutics, Inc.'s common stock, primarily through exercisable warrants.

Summary

• A group of reporting persons, including Biotechnology Value Fund, L.P., BVF II, L.P., and Biotechnology Value Trading Fund OS LP, along with their general partners and affiliates, collectively hold a beneficial ownership in CytomX Therapeutics, Inc.
• The aggregate beneficial ownership for the collective reporting group (BVF Partners L.P., BVF Inc., and Mark N. Lampert) is 5,769,231 shares.
• This represents approximately 3.5% of the outstanding common stock, calculated based on 157,544,369 shares outstanding as of May 13, 2025, plus the shares underlying the warrants.
• The ownership is primarily through Tranche 2 Warrants, which are exercisable at $3.77 per share and are set to expire on July 3, 2026.
• A 'Warrants Blocker' limits the exercise of warrants to prevent any holder (together with its affiliates) from beneficially owning more than 9.99% of the outstanding shares immediately after such exercise; as of July 9, 2025, this blocker did not prohibit the exercise of any held warrants.

Sentiment

Score: 6

Explanation: The document is a routine passive ownership disclosure. It is neutral in terms of company performance but can be seen as slightly positive due to a specialized fund maintaining a significant stake, implying continued belief in the company's long-term prospects without activist intent.

Positives

• A significant institutional investor group maintains a stake in CytomX Therapeutics, indicating continued interest in the company.
• The disclosed ownership is passive, suggesting no immediate intent for activist intervention or changes in corporate control.

Risks

• The value of the warrants held by the reporting persons is directly tied to the market price fluctuations of CytomX Therapeutics' common stock.
• The 'Warrants Blocker' could potentially limit the full exercise of the warrants if the beneficial ownership threshold of 9.99% is approached or exceeded.

Future Outlook

The document is a passive ownership disclosure and does not provide forward-looking statements or guidance regarding CytomX Therapeutics' future operations or financial performance. It only indicates the expiration date of the warrants on July 3, 2026.

Industry Context

This filing reflects a passive investment by a specialized biotechnology fund in a publicly traded biotech company. Such filings are common for institutional investors accumulating stakes in companies within their investment focus. It does not provide specific insights into broader industry trends beyond the general interest of a biotech-focused fund in CytomX Therapeutics.

Comparison to Industry Standards

• This Schedule 13G filing is a standard regulatory disclosure for passive ownership exceeding certain thresholds and does not contain performance metrics for comparison to industry standards or specific comparable companies/projects. It solely details the ownership structure of a specific investor group in CytomX Therapeutics.

Stakeholder Impact

• Shareholders: Provides transparency regarding a significant institutional investor's stake, which could be viewed positively as a vote of confidence, albeit passive.

Next Steps

• The Tranche 2 Warrants held by the reporting persons will expire on July 3, 2026, requiring a decision on exercise or sale before that date.

Key Dates

Keywords

CytomX Therapeutics, Biotechnology Value Fund, BVF, Schedule 13G, Beneficial Ownership, Common Stock, Warrants, SEC Filing, Institutional Investor, Passive Investment, Biotech